Jan Tennvall1, Boudewijn Brans. 1. Department of Oncology, Lund University Hospital, 221 85 Lund, Sweden. Jan.Tennvall@med.lu.se
Abstract
INTRODUCTION: (32)P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom (32)P is the most optimal treatment option, an assertion supported by two large studies with long follow-up. PURPOSE: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for (32)P phosphate therapy.
INTRODUCTION: (32)P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom (32)P is the most optimal treatment option, an assertion supported by two large studies with long follow-up. PURPOSE: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for (32)P phosphate therapy.
Authors: Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-13 Impact factor: 9.236
Authors: Yulan Cheng; Ana P Kiess; Joseph M Herman; Martin G Pomper; Stephen J Meltzer; John M Abraham Journal: PLoS One Date: 2015-06-01 Impact factor: 3.240